O²-sulfo-D-galactose | 19237-29-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: O²-sulfo-D-galactose
• 英文别名: D-galactose 2-sulfate；galactose sulfate；Galactose 2-sulfate；[(2R,3S,4S,5R)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl] hydrogen sulfate
• CAS: 19237-29-7
• 化学式: C₆H₁₂O₉S
• 分子量: 260.222
• InChiKey: SZEJJURKOHIFBI-DPYQTVNSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.8
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  170
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  O²-sulfo-D-galactose 在 盐酸 作用下， 以 水 为溶剂， 生成 口服葡萄糖
  参考文献：
  名称：

  On the desulphation of carbohydrate sulphates

  摘要：

  DOI：

  10.1016/0008-6215(83)88470-5

文献信息

• Low-emulsifier or emulsifier-free systems of the oil-in-water type with a content of stabilizers and an amino-substituted hydroxybenzophenone
  申请人：——

  公开号：US20030124158A1

  公开（公告）日：2003-07-03

  Cosmetic or dermatological preparations which represent finely disperse systems of the oil-in-water type, comprising a) an oil phase, b) a water phase, c) one or more stabilizers, d) at most 2.00% by weight of one or more emulsifiers, and e) an amino-substituted hydroxybenzophenone of the formula I 1

  化妆品或皮肤科制剂，代表油包水型的细分散系统，包括 a) 油相， b) 水相， c) 一种或多种稳定剂， d) 最多占总重量的2.00%的一种或多种乳化剂，以及 e) 公式I的氨基取代羟基苯酮 1
• Use of multivalent glycodendrimers to inhibit the activity of human immunodeficiency virus
  申请人：——

  公开号：US20040180852A1

  公开（公告）日：2004-09-16

  The present invention relates to compositions and methods for inhibiting the interaction of a ligand and receptor. In particular, compositions are methods are provided for inhibition of interaction between a virus, especially HIV, and a receptor. Inhibition of such ligand/receptor interaction is advantageous in inhibiting infection of a cell with a virus. Further, an inhibitor of ligand/receptor interaction serves as a standard in assays of inhibition in vitro or in vivo. In a particular embodiment, a composition according to the invention includes a compound having the formula: [(X)—(Y)] p -Z where X is 1 and where Q1 and Q2 are each independently H, a bond to Y, or a bond to Z, where at least one of Q1 or Q2 is a bond to Y or a bond to Z; where R1, R4, R6 and R8 are each H; R2, R3, and R5 are each independently OH, OSO3D, or OPO3D, and R7 is CH20H, CH2OSO3D or CH2OPO3D; where D is H or a cation selected from the group consisting of: alkali metal cations, alkaline earth metal cations, ammonium cations, quaternary ammonium cations and amine cations; and where at least one of R2, R3, R5 and R7 is a sulfur or phosphate containing group; where Y is an optional linker, Z is a multivalent support, and p is an integer in the range of 1-2000 inclusive.

  本发明涉及用于抑制配体和受体相互作用的组合物和方法。具体而言，提供了用于抑制病毒（特别是HIV）与受体之间相互作用的组合物和方法。抑制此类配体/受体相互作用有助于抑制细胞感染病毒。此外，配体/受体相互作用的抑制剂可作为体外或体内抑制测定的标准。在一个特定实施例中，根据本发明的组合物包括具有以下结构的化合物：[(X)—(Y)] p -Z，其中X为1，Q1和Q2分别独立地为H、与Y的键或与Z的键，其中Q1或Q2中至少有一个是与Y的键或与Z的键；R1、R4、R6和R8各自为H；R2、R3和R5各自独立地为OH、OSO3D或OPO3D，R7为 0H、CH2OSO3D或 OPO3D；D为H或从以下群组中选择的阳离子：碱金属阳离子、碱土金属阳离子、铵阳离子、季铵阳离子和胺阳离子；其中R2、R3、R5和R7中至少有一个是含硫或磷酸酯基团；Y为可选的连接剂，Z为多价支持体，p为在1-2000范围内的整数。
• [EN] SULFATED GLYCOPOLYMERS<br/>[FR] GLYCOPOLYMÈRES SULFATÉS
  申请人：UNIV NOTTINGHAM

  公开号：WO2018007827A1

  公开（公告）日：2018-01-11

  This invention relates to sulfated glycopolymers comprising a polymeric backbone wherein at least one of the monomeric units which form the backbone has a pendant galactose and/or N-acetyl galactosamine group, wherein one or more of the pendant galactose groups are sulfated at one or more of positions 2, 3, 4 and 6 and/or one or more of the N-acetyl galactosamine groups are sulfated at one or more of positions 3, 4 and 6. The invention also relates to the use of sulfated glycopolymers in the treatment of a disease, for example, IRI, acute kidney injury, myocardial ischaemia, ischaemic stroke, cancer or an autoimmune disease.

  该发明涉及含有聚合骨架的磺酸基糖聚合物，其中形成骨架的单体单元中至少有一个带有半乳糖和/或N-乙酰半乳糖胺基团，其中一个或多个半乳糖基在2、3、4和6位置之一或多个位置上被磺酸化和/或一个或多个N-乙酰半乳糖胺基在3、4和6位置之一或多个位置上被磺酸化。该发明还涉及将磺酸基糖聚合物用于治疗疾病，例如IRI、急性肾损伤、心肌缺血、缺血性中风、癌症或自身免疫疾病。
• Glycomimetic inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from pseudomonas
  申请人：Magnani L. John

  公开号：US20070037775A1

  公开（公告）日：2007-02-15

  Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. A compound useful in the present methods may be used in combination with a therapeutic agent or may be linked to a therapeutic agent. Pseudomonas bacteria may be inhibited by blocking colonization, inhibiting virulence factors, arresting growth or killing the bacteria.

  提供与铜绿假单胞菌相关的组合物和方法。这些组合物和方法可用于诊断和治疗涉及铜绿假单胞菌感染的医疗状况。这些感染包括囊性纤维化患者肺部中的铜绿假单胞菌。在目前的方法中有用的化合物可以与治疗剂结合使用，或者可以与治疗剂连接。通过阻止定植、抑制毒力因子、阻止生长或杀死细菌可以抑制铜绿假单胞菌。
• [EN] COMPOSITION COMPRISING SULPHATED GALACTOSE, AND IMPLEMENTATIONS THEREOF<br/>[FR] COMPOSITION COMPRENANT DU GALACTOSE SULFATÉ ET SES MODES DE RÉALISATION
  申请人：SEA6ENERGY PVT LTD

  公开号：WO2020095329A1

  公开（公告）日：2020-05-14

  The present disclosure discloses a composition comprising: (a) at least one sulphated galactose; and (b) at least one saccharide selected from a group consisting of disaccharide, trisaccharide, tetrasaccharide, pentasaccharide, and salts thereof. The present disclosure further discloses a weight percentage of the at least one sulphated galactose to be in a range of 15-90% with respect to the total sugar content. Further, the present disclosure discloses a use of the composition for protecting/treating plants from infection. Also provided is a use of the composition for protecting/treating animals from infection. The present disclosure discloses a use of sulphated galactose for protecting/treating plants from infection. Also provided is a use of sulphated galactose for protecting/treating animals from infection. The present disclosure also discloses a method for preparing the composition as described herein.

  本公开披露了一种组合物，包括：（a）至少一种硫酸化半乳糖；和（b）至少一种从双糖、三糖、四糖、五糖和其盐组成的群体中选择的低聚糖。本公开披露进一步披露了至少一种硫酸化半乳糖的重量百分比在总糖含量的15-90％范围内。此外，本公开披露了将该组合物用于保护/治疗植物免受感染的用途。还提供了将该组合物用于保护/治疗动物免受感染的用途。本公开披露了将硫酸化半乳糖用于保护/治疗植物免受感染的用途。还提供了将硫酸化半乳糖用于保护/治疗动物免受感染的用途。本公开披露还披露了制备上述组合物的方法。